Melo, Carina Mucciolo
Meneghetti, Maria Cecilia Zorel
Nader, Helena Bonciani
Klemke, Richard L.
Pinhal, Maria Aparecida Silva
Total Authors: 8
 Fac Med ABC, Dept Biochem, Santo Andre, SP - Brazil
 Univ Fed Sao Paulo, Dept Biochem Mol Biol, Sao Paulo - Brazil
 Univ Calif San Diego, Sch Med, Dept Pathol, La Jolla, CA 92093 - USA
 Comenius Univ, Jessenius Fac Med Martin, Biomed Ctr Martin, Dept Mol Med, Martin - Slovakia
Total Affiliations: 4
FRONTIERS IN ONCOLOGY;
AUG 4 2021.
Web of Science Citations:
Angiogenesis is the formation of new vessels from pre-existing vasculature. The heparan sulfate chains from endothelial cell proteoglycans interact with the major angiogenic factors, regulating blood vessels ` formation. Since the FDA ` s first approval, anti-angiogenic therapy has shown tumor progression inhibition and increased patient survival. Previous work in our group has selected an HS-binding peptide using a phage display system. Therefore, we investigated the effect of the selected peptide in angiogenesis and tumor progression. The HS-binding peptide showed a higher affinity for heparin N-sulfated. The HS-binding peptide was able to inhibit the proliferation of human endothelial umbilical cord cells (HUVEC) by modulation of FGF-2. It was verified a significant decrease in the tube formation of human endothelial cells and capillary formation of mice aorta treated with HS-binding peptide. HS-binding peptide also inhibited the formation of sub-intestinal blood vessels in zebrafish embryos. Additionally, in zebrafish embryos, the tumor size decreased after treatment with HS-binding peptide. (AU)